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Coronary Heart Disease
Isolated Low Levels of High-Density Lipoprotein Cholesterol
Are Associated With an Increased Risk of Coronary
Heart Disease
An Individual Participant Data Meta-Analysis of 23 Studies in the
Asia-Pacific Region
Rachel R. Huxley, DPhil; Federica Barzi, PhD; Tai Hing Lam, MD; Sebastien Czernichow, PhD;
Xianghua Fang, PhD; Tim Welborn, PhD; Jonathan Shaw, MD; Hirotsugu Ueshima, MD;
Paul Zimmet, PhD; Sun Ha Jee, PhD; Jeetesh V. Patel, MD; Ian Caterson, PhD;
Vlado Perkovic, PhD; Mark Woodward, PhD; for the Asia Pacific Cohort Studies Collaboration and the
Obesity in Asia Collaboration
Background—Previous studies have suggested that there is a novel dyslipidemic profile consisting of isolated low
high-density lipoprotein cholesterol (HDL-C) level that is associated with increased risk of coronary heart disease, and
that this trait may be especially prevalent in Asian populations.
Methods and Results—Individual participant data from 220 060 participants (87% Asian) in 37 studies from the
Asia-Pacific region were included. Low HDL-C (HDL 1.03 mmol/L in men and 1.30 mmol/L in women) was seen
among 33.1% (95% confidence interval [CI], 32.9–33.3) of Asians versus 27.0% (95% CI, 26.5–27.5) of non-Asians
(P0.001). The prevalence of low HDL-C in the absence of other lipid abnormalities (isolated low HDL-C) was higher
in Asians compared with non-Asians: 22.4% (95% CI, 22.2–22.5) versus 14.5% (95% CI, 14.1–14.9), respectively
(P0.001). During 6.8 years of follow-up, there were 574 coronary heart disease and 739 stroke events. There was an
inverse relationship between low HDL-C with coronary heart disease in all individuals (hazard ratio, 1.57; 95% CI,
1.31–1.87). In Asians, isolated low levels of HDL-C were as strongly associated with coronary heart disease risk as low
levels of HDL-C combined with other lipid abnormalities (hazard ratio, 1.67 [95% CI, 1.27–2.19] versus 1.63 [95% CI,
1.24–2.15], respectively). There was no association between low HDL-C and stroke risk in this population (hazard ratio,
0.95 [95% CI, 0.78 to 1.17] with nonisolated low HDL-C and 0.81 [95% CI, 0.67–1.00] with isolated low HDL-C).
Conclusion—Isolated low HDL-C is a novel lipid phenotype that appears to be more prevalent among Asian
populations, in whom it is associated with increased coronary risk. Further investigation into this type of
dyslipidemia is warranted. (Circulation. 2011;124:2056-2064.)
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The direct but opposing relationships of low-density lipo-protein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) with coronary heart disease (CHD) risk
are well characterized in many populations.1–3 There is also
increasing recognition of the importance of HDL-C in deter-
mining coronary risk independently of LDL-C levels.4,5
Moreover, some studies suggest that isolated low HDL-C, a
condition that describes the coexistence of low HDL-C in
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conjunction with normal LDL-C and triglyceride levels, has
a coronary risk equivalent to that of elevated LDL-C.6–8
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Survey data suggest that the prevalence of low HDL-C,
either in isolation or in conjunction with abnormal LDL-C or
triglyceride levels, differs substantially between countries and
ethnic groups, and published values for the prevalence of
isolated low HDL-C range from 6% to 34%.6,9–11 However,
individuals with this lipid phenotype are unlikely to be
considered for pharmacotherapy partly because their LDL-C
and total cholesterol levels fall within current guidelines, and
partly because there is insufficient randomized evidence
unequivocally demonstrating that raising HDL-C levels re-
duces cardiovascular risk.12
Here, we determine whether isolated low HDL-C is a form
of dyslipidemia that occurs more frequently in Asian popu-
lations using data from 2 large-scale collaborations of pro-
spective cohorts and cross-sectional studies from the Asia-
Pacific region, namely the Asia Pacific Cohort Studies
Collaboration (APCSC) and the Obesity in Asia Collabora-
tion (OAC). We also examine whether isolated low HDL-C is
independently associated with increased risk of CHD and stroke
and if there is a particular phenotype associated with low HDL-C
based on routinely measured clinical characteristics.
Methods
Asia Pacific Cohort Studies Collaboration
Details of APCSC, including study identification, data collection,
and event verification, are given elsewhere.13,14 All studies included
in APCSC were conducted prospectively in populations from the
Asia-Pacific region, had at least 5000 person-years of follow-up, and
recorded age, sex, and blood pressure (BP) at baseline, as well as
vital status at the end of the follow-up. Lipid measurements were
determined with serum samples, which were obtained while fasting
in 93% of participants. Information regarding the method of
cholesterol analysis was available for 70% of all participants, of
whom 96% used enzymatic methods. Most studies additionally
recorded current smoking status (current/not current) at baseline. BP
was measured at rest in the seated position with a standard mercury
sphygmomanometer in most studies.
Obesity in Asia Collaboration
Details of OAC, including study identification, data collection, and
event verification, are given elsewhere.15,16 Studies were eligible if
they contained information on age, sex, weight, height, waist
circumference, hip circumference, fasting plasma glucose, and BP
and measures on at least 1 lipid variable (total cholesterol, HDL-C,
LDL-C, or triglycerides).
All of the included studies from both the APCSC and OAC were
classified as Asian if study members were recruited from mainland
China, Hong Kong, India, Japan, Korea, the Philippines, Singapore,
South Korea, Taiwan, or Thailand; they were classified as Australia/
New Zealand if participants were drawn from Australia or New
Zealand. This classification largely represented a split by ethnicity
into Asians and non-Asians.
Statistical Methods
Participants without information on lipids were excluded from these
analyses. When not measured directly, LDL-C was calculated from
the Friedewald formula in samples in which triglyceride levels were
400 mg/dL.17 National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) guidelines were
used to identify people with low values of HDL-C (1.03 mmol/L
in men, 1.30 mmol/L in women), high values of LDL-C
(4.14 mmol/L), and high values of triglycerides (2.26 mmol/L).18
These guidelines were chosen to facilitate comparisons with previous
work. Venn diagrams were constructed to illustrate the frequency of
different forms of dyslipidemia within Asians and non-Asians.
Because cigarette smoking is negatively associated with HDL-C
levels, the frequency of lipid abnormalities was also examined by
smoking status separately within Asia and Australia/New Zealand.
The outcomes analyzed in this study were fatal or nonfatal CHD
(International Classification of Disease codes 410, 411, 412, 413,
414, and 798) and stroke (codes 430–438). Fatal CHD and stroke
events were recorded in 37 studies from the APCSC using a variety
of methods, most often through death registrations or personal
contact with subjects or relatives. Nonfatal events were recorded in
8 studies through hospital records or personal contact. The median
follow-up was 6.6 years in Asia and 8.3 years in non-Asian
countries.
Individuals were divided into 3 mutually exclusive groups accord-
ing to lipid levels: normal HDL-C, isolated low HDL-C, and
nonisolated low HDL-C (ie, low HDL-C combined with elevated
LDL-C and/or triglycerides). Differences in the distribution of BP
and anthropometry across these groups were assessed with general
linear models, and differences in the percentages of smoking and
diabetes mellitus were assessed with logistic regression models. All
models accounted for the confounding effects of age and study.
Hazard ratios (HRs) for CHD and stroke events were calculated with
Cox proportional hazard models, with corresponding 95% confi-
dence intervals (CIs) derived with floating absolute risks and taking
those with normal HDL-C as the reference group. The continuous
relationships between HDL-C and cardiovascular outcomes are
described in detail elsewhere.4 In the main analysis, Cox models
were adjusted by age, systolic BP, and current smoking and stratified
by study and sex. A sensitivity analysis was performed comparing
current smokers with not-current smokers separately within Asia and
Australia/New Zealand in models adjusted for age and systolic BP
and stratified by study and sex. In a subgroup of the population
(n64 310), information on alcohol consumption at study baseline
was available (yes/no); among this group, the models were rerun
stratifying by alcohol status. In secondary analyses, we examined the
relationships with cardiovascular outcomes when low HDL-C level
was defined according to the modified World Health Organization
(WHO) guidelines (1.0 mmol/L in men and 0.9 mmol/L in
women) and the European Group for Insulin Resistance (EGIR)
guidelines (1.0 mmol/L).19
All analyses were conducted with SAS version 9.1 (SAS Institute,
Inc, Cary, NC).
Results
Information was available on 69 145 eligible study partici-
pants from 24 studies from the APCSC (Table 1) and 150 915
from 13 studies in the OAC (Table 2). Overall, 87% of men
and 86% of women were from Asia. The overall mean levels
of cardiovascular risk factors for Asians and non-Asians are
summarized in Table 3.
In the Asian cohorts, one third (33%) displayed low levels
of HDL-C (n63 316), and two thirds of these individuals
(22% overall) had isolated levels of low HDL-C (Figure 1A).
These estimates were comparable in current (Figure Ia in the
online-only Data Supplement) and not-current (Figure Ib in
the online-only Data Supplement) smokers. High levels of
LDL-C either with or without other colipid abnormalities
occurred in 13% of the population. When examined by
country, the frequency of low HDL-C varied between one
quarter and one third of the study population, with the notable
exceptions of Singapore and India, where 50% of the
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population was affected (Table I in the online-only Data
Supplement).
In non-Asians, 27% of individuals (n7754) had low
levels of HDL-C either with or without associated colipid
abnormalities. Isolated low HDL-C occurred in half of these
individuals (n4021, 14% of non-Asians; Figure 1B). These
estimates were similar in current and not-current smokers
(Figure IIa and IIb in the online-only Data Supplement,
Table 1. Baseline Study Characteristics of Contributing Studies From the Asia Pacific Cohort Studies Collaboration
Cohort Country n
Age,
y
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
LDL-C,
mmol/L
BMI,
kg/m2
SBP,
mm Hg
Smoking,
%
Diabetes
Mellitus,
% WC, cm
Hip
Circumference,
cm
Obesity,*
%
ALSA Australia 1121 78 (6) 5.8 (1.1) 1.5 (0.7) 1.3 (0.4) 3.8 (1.0) 25.7 (3.9) 149 (22) 8.3 7.1 . . . . . . 13.0
ANHF Australia 8924 43 (13) 5.5 (1.1) 1.4 (0.7) 1.3 (0.4) 3.5 (1.0) 25.3 (4.2) 126 (18) 23.8 1.7 83 (13) 100 (9) 12.2
Busselton Australia 1585 44 (17) 5.7 (1.2) 1.2 (0.7) 1.5 (0.4) 3.6 (1.1) 24.6 (3.7) 129 (20) 24.0 7.3 . . . . . . 8.0
Perth Australia 5826 45 (13) 5.6 (1.1) 1.2 (0.7) 1.4 (0.4) 3.7 (1.0) 25.5 (4.2) 130 (21) 25.4 2.5 . . . . . . 13.2
Aito town Japan 893 52 (7) 4.7 (0.8) 1.3 (0.4) 1.4 (0.4) 2.6 (0.8) 22.6 (3.0) 139 (20) 30.8 1.7 . . . . . . 4.5
Akabane Japan 1819 54 (8) 5.0 (0.9) 1.2 (0.7) 1.2 (0.3) 3.2 (0.8) 22.5 (3.0) 125 (19) 27.8 2.4 . . . . . . 4.1
Anzhen02 China 4078 47 (8) 4.7 (0.9) 1.2 (0.7) 1.4 (0.4) 2.7 (0.8) 24.0 (3.3) 122 (18) 20.6 10.7 80 (9) 97 (7) 11.1
Beijing Aging China 1675 69 (8) 4.4 (1.0) 1.5 (0.8) 1.5 (0.6) 3.0 (1.0) 23.3 (3.9) 141 (25) 30.6 29.4 . . . . . . 11.4
CISC China 164 45 (9) 5.0 (0.8) 0.7 (0.6) 1.1 (0.3) 2.8 (1.2) 22.9 (2.7) 123 (20) 73.6 . . . . . . 4.3
Civil Service
Workers
Japan 8910 47 (5) 5.2 (0.9) 1.4 (0.8) 1.4 (0.4) 3.1 (0.8) 22.4 (2.7) 125 (18) 37.8 1.7 . . . . . . 3.0
CVDFACTS China 460 45 (16) 4.8 (1.0) 1.2 (0.7) 1.3 (0.4) 3.0 (0.9) 23.2 (3.4) 113 (19) 22.4 3.0 . . . . . . 8.1
EGAT Thailand 3390 43 (5) 5.7 (1.1) 1.6 (0.8) 1.2 (0.3) 3.8 (1.0) 23.0 (3.1) 120 (16) 43.0 2.5 . . . . . . 6.6
Fangshan China 774 47 (9) 4.6 (1.0) 1.5 (0.7) 1.4 (0.4) 2.5 (0.9) 24.9 (3.6) 132 (25) 38.4 6.3 . . . . . . 18.9
Guangzhou
Occupational
China 9106 43 (6) 5.2 (1.0) 1.4 (0.7) 1.3 (0.5) 3.3 (1.1) 22.6 (3.3) 113 (15) 44.4 7.9 . . . . . . 7.6
Hong Kong Hong Kong 183 79 (7) 5.2 (0.9) 1.6 (1.0) 1.5 (0.5) 3.0 (0.8) 22.0 (3.6) 148 (22) 16.9 10.4 81 (10) 91 (8) 7.3
Huashan China 1744 53 (12) 4.6 (0.9) 1.4 (0.7) 1.4 (0.4) 2.6 (0.8) 23.3 (3.4) 126 (21) . . . 10.6 . . . . . . 8.6
Konan Japan 1206 52 (16) 4.9 (0.9) 1.1 (0.6) 1.6 (0.4) 2.8 (0.8) 21.9 (3.0) 130 (19) 29.7 12.6 . . . . . . 3.2
Miyama Japan 404 59 (9) 5.1 (0.9) 1.2 (0.6) 1.3 (0.3) 3.2 (0.8) 22.3 (3.0) 129 (23) 23.6 2.2 . . . . . . 4.2
Ohasama Japan 1869 58 (11) 5.0 (0.9) 1.5 (0.8) 1.4 (0.4) 2.9 (0.8) 23.2 (3.1) 127 (17) 20.1 9.2 . . . . . . 7.3
Seven Cities
Cohorts
China 6050 58 (10) 4.9 (1.3) 1.6 (0.7) 1.5 (0.5) 2.7 (1.3) 22.9 (3.8) 134 (25) 33.9 1.6 . . . . . . 9.9
Shigaraki Town Japan 3678 57 (14) 5.0 (0.9) 1.4 (0.7) 1.5 (0.4) 2.9 (0.8) 22.5 (3.1) 132 (20) 28.5 7.1 . . . . . . 4.8
Singapore Heart Singapore 2063 41 (13 5.8 (1.1) 1.3 (0.8) 1.0 (0.3) 4.2 (1.0) 23.5 (4.4) 123 (21) 20.8 10.9 . . . . . . 15.4
Singapore NHS92 Singapore 3223 39 (12) 5.3 (1.0) 1.3 (0.8) 1.3 (0.3) 3.5 (0.9) 23.2 (4.2) 118 (18) 18.0 9.1 . . . . . . 11.6
TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; SBP,
systolic blood pressure; WC, waist circumference; ALSA, Australian Longitudinal Study of Aging; ANHF, Australian National Heart Foundation; CISC, Capital Iron and
Steel Company; CVDFACTS, The Cardiovascular Disease Risk Factors Two-Townships Study; NHS92, National Health Survey 1992; and EGAT, Electricity Generating
Authority of Thailand. Ellipses indicate missing data. Values are mean (SD) unless otherwise specified.
*Obesity was defined as body mass index 30 kg/m2 in non-Asians and 28 kg/m2 in Asians.
Table 2. Baseline Study Characteristics of Contributing Studies From the Obesity in Asia Collaboration
Cohort Country n
Age,
y
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
LDL-C,
mmol/L
BMI,
kg/m2
SBP,
mm Hg
Smoking,
%
Diabetes
Mellitus,
%
WC,
cm
Hip
Circumference,
cm
Obesity,
%
AUSDIAB Australia 10 991 52 (15) 5.6 (1.0) 1.5 (0.8) 1.4 (0.4) 3.5 (0.9) 26.9 (4.9) 129 (19) 15.6 5.1 91 (14) 105 (10) 21.7
China (Zhou) China 43 209 49 (12) 4.7 (1.0) 1.3 (0.7) 1.4 (0.4) 2.7 (0.9) 23.7 (3.6) 126 (22) 29.0 4.8 79 (10) 94 (8) 11.3
EGAT2 Thailand 2746 43 (5) 6.1 (1.1) 1.6 (0.8) 1.5 (0.4) 3.9 (1.1) 23.8 (3.6) 123 (21) 25.8 4.0 84 (10) 96 (7) 11.4
HK (Lam) Hong Kong 1499 37 (9) 5.1 (0.9) 1.1 (0.8) 1.4 (0.4) 3.3 (0.9) 23.3 (3.2) 118 (15) 14.5 2.3 78 (9) 93 (6) 7.3
India (Mohan) India 2422 41 (7) 4.6 (1.1) 1.6 (0.8) 1.0 (0.3) 3.0 (1.1) 23.9 (3.6) 121 (13) 31.7 9.9 87 (10) 90 (7) 11.2
India (Mohan) India 619 48 (9) 5.3 (1.0) 1.5 (1.0) 1.3 (0.4) 3.3 (0.9) 27.0 (4.6) 119 (15) 4.4 2.4 87 (12) 99 (10) 34.0
India (Mohan) India 2300 40 (13) 4.6 (1.0) 1.3 (0.7) 1.1 (0.3) 2.9 (0.8) 22.8 (4.0) 119 (18) 18.5 8.4 83 (11) 94 (9) 8.8
India (Mohan) India 4115 47 (9) 4.8 (1.0) 1.7 (0.7) 1.1 (0.2) 3.0 (0.9) 23.3 (4.9) 119 (20) 20.2 8.5 81 (13) 90 (11) 16.3
India (Lear) India 299 39 (13) 4.4 (1.0) 1.2 (0.7) 1.4 (0.3) 2.5 (0.9) 24.9 (4.3) 114 (14) 5.7 1.4 81 (11) 99 (9) 16.8
India (Patel) India 271 50 (14) 4.9 (1.0) 1.0 (0.5) 1.2 (0.3) 3.3 (0.9) 21.0 (3.9) 116 (22) . . . 7.8 76 (12) 92 (8) 4.8
INTERASIA Thailand 4876 54 (12) 5.4 (1.2) 1.6 (0.8) 1.2 (0.3) 3.5 (1.1) 24.2 (4.4) 122 (20) 20.9 9.4 82 (12) 94 (9) 17.4
KNHANES Korea 7944 45 (16) 4.9 (1.0) 1.4 (0.7) 1.3 (0.3) 2.9 (0.9) 23.2 (3.2) 126 (20) . . . 9.1 80 (9) 93 (7) 7.1
Taiwan Taiwan 69 624 43 (14) 5.2 (1.0) 1.3 (0.7) 1.3 (0.4) 3.3 (0.8) 23.1 (3.4) 128 (23) . . . 3.6 77 (10) 94 (6) 7.9
TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; SBP,
systolic blood pressure; WC, waist circumference; AUSDIAB, Australian Diabetes Obesity and Lifestyle Study; EGAT2, Electricity Generating Authority of Thailand 2;
INTERASIA, International Collaborative Study of Cardiovascular Disease in Asia; and KNHANES, Korean National Health and Nutrition Examination Survey. Ellipses
indicate missing data. Values are mean (SD) unless specified otherwise.
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respectively). Overall, the frequency of high LDL-C was
twice as high in Asian as in non-Asian populations (26.1%
[95% CI, 25.6–26.6] versus 13.4% [95% CI, 13.3–13.6];
P0.001; Figure 2B), whereas the frequency of elevated
triglycerides was comparable between non-Asians and Asians
(12.6% [95% CI, 12.2–13.0] versus 11.6% [95% CI, 11.5–
11.8], respectively, although the P for the regional difference
was 0.0001 because of the large sample size).
Table 4 shows the mean phenotypic characteristics of
individuals with nonisolated low HDL-C, isolated low
HDL-C, and normal levels of HDL-C. Overall, low HDL-C
levels were more associated with higher values of body mass
index and waist circumference and a higher frequency of
diabetes mellitus compared with normal levels of HDL-C,
regardless of sex and region. There were no consistent
associations between BP and smoking status with HDL-C
levels within the sex and region groups.
During a median follow-up of 6.8 years, there were 574
fatal and nonfatal CHD events (42% Asia) and 739 fatal and
nonfatal stroke events (76% Asia). Of these, there were 253
ischemic and 186 hemorrhagic strokes (the remainder were
unclassified). In adjusted analyses, nonisolated low levels of
HDL-C were associated with a nearly 60% higher risk of
CHD compared with normal levels of HDL-C (HR, 1.57;
95% CI, 1.31–1.87). This association was observed in all
individuals regardless of sex, region, and smoking status
(Figure 2). This estimate did not differ materially when either
the WHO or EGIR cut points for HDL-C were used (Table IIa
and IIb in the online-only Data Supplement). In the subgroup
for whom information was available on alcohol consumption
at study baseline (yes/no), there was no evidence of interac-
tion in the association between low levels of HDL-C with
subsequent CHD (HR, 1.55 [ 95% CI, 1.18–2.04] in current
drinkers versus 1.59 [95% CI, 1.26–2.00] in nondrinkers;
Table 3. Summary of the Baseline Characteristics of the Overall Study Participants From the Asia Pacific
Cohort Studies Collaboration and the Obesity in Asia Collaboration
Men Women
Mean (SD) Mean (SD)
Variable n Asian Non-Asian n Asian Non-Asian
Age, y 108 455 46.7 (12.7) 48.5 (15.6) 111 605 46.4 (13.2) 48.1 (15.2)
Total cholesterol, mmol/L 108 455 5.05 (1.03) 5.56 (1.04) 111 605 5.02 (1.03) 5.59 (1.11)
Triglycerides, mmol/L 108 455 1.48 (0.78) 1.51 (0.81) 111 605 1.24 (0.69) 1.26 (0.70)
HDL-C, mmol/L 108 455 1.24 (0.37) 1.24 (0.32) 111 605 1.43 (0.38) 1.53 (0.38)
LDL-C, mmol/L 108 455 3.13 (0.98) 3.64 (0.94) 111 605 3.05 (0.95) 3.49 (0.98)
Body mass index, kg/m2 103 789 23.4 (3.31) 26.3 (3.81) 108 480 23.1 (3.76) 25.7 (5.07)
Waist circumference, cm 65 906 82.5 (9.5) 93.8 (11.5) 71 580 74.5 (9.8) 81.4 (13.1)
SBP, mm Hg 76 152 125.9 (19.5) 132.1 (18.2) 76 207 123.5 (22.0) 125.8 (20.4)
DBP, mm Hg 76 171 78.7 (12.0) 79.4 (10.9) 76 209 75.9 (11.9) 72.1 (11.1)
Smoking, % 65 803 50.4 23.3 63 154 6.9 17.5
Diabetes mellitus, % 103 903 5.6 4.4 108 705 4.9 4.6
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and
DBP, diastolic blood pressure.
Figure 1. A and B, Prevalence of lipid phenotypes in adult Asian populations (A; n191 317) and adult populations from Australia and
New Zealand (B; n28 743). HDL indicates high-density lipoprotein; HDL-C, HDL cholesterol; LDL, low-density lipoprotein; and TG,
triglycerides.
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P0.99). For purposes of comparison, the risk of CHD
associated with LDL-C level was also determined. In this
population, the risk of CHD was nearly 60% higher in those
with high levels of LDL-C compared with those with normal
levels of LDL-C (HR, 1.58; 95% CI, 1.30–1.93).
There was some evidence that isolated low HDL-C in-
creased the risk of incurring a CHD event compared with
normal HDL-C, although the relationship was nonsignificant
(HR, 1.17; 95% CI, 0.95–1.46). This estimate did not alter
materially when the EGIR cut points were used; however,
there was no association when the modified WHO cut points
were used (Table II in the online-only Data Supplement),
although this may have been a chance finding given the small
number of events in those with isolated low HDL-C (n18).
In sensitivity analyses, the relationship between isolated low
HDL-C and CHD was particularly apparent in Asian cohorts
compared with studies from Australia/New Zealand (HR,
1.67 [95% CI, 1.27–2.19] versus 0.79 [95% CI, 0.54 – 1.14];
P for regional interaction0.016) and in men compared with
women (HR, 1.30 [95% CI, 1.01–1.67] versus 0.91 [95% CI,
0.58–1.43]; P for sex interaction0.04). There was no
evidence of an interaction with smoking (P0.95) or alcohol
(P0.99). In Asians, isolated low HDL-C was as strongly
associated with CHD risk as nonisolated low levels of
HDL-C (HR, 1.67 [95% CI, 1.27–2.19] versus 1.63 [95% CI,
1.24–2.15], respectively). These results did not differ mate-
rially according to how low HDL-C level was defined (Table
IIa and IIb in the online-only Data Supplement) or after
adjustment for LDL-C and triglycerides (Table III in the
online-only Data Supplement).
In adjusted analyses, nonisolated low HDL-C was not
associated with risk of stroke compared with those individu-
als with normal HDL-C (HR, 0.95; 95% CI, 0.78–1.17), both
in the overall analysis and within any of the subgroups
(Figure 3). This remained unchanged when either the WHO
or EGIR cut points for low HDL-C were used (Table IVa and
IVb in the online-only Data Supplement). Furthermore, there
was no evidence of an interaction between HDL-C level and
alcohol consumption (P0.70).
In those with isolated low HDL-C, there was an 20%
lower risk of stroke compared with those with normal HDL-C
both in the overall population and within major subgroups
(Figure 3). This remained true regardless of the cut point used
to define low HDL-C (Table IVa and IVb in the online-only
Data Supplement) and remained unchanged after adjustment
for LDL-C and triglycerides (Table III in the online-only
Data Supplement).
Discussion
Data from 2 large collaborations of studies with information
on nearly 220 000 individuals conducted within populations
of the Asia-Pacific region suggest a phenotype of dyslipid-
emia that is highly prevalent, but not unique, to Asian
populations. The most frequent pattern of dyslipidemia
among the Asian population (observed in approximately one
third) was low HDL-C levels. In two thirds of these individ-
uals, low levels of HDL-C occurred in the absence of any
associated colipid abnormality, and this was the most com-
mon individual lipid abnormality. In non-Asians, low levels
of HDL-C were evident in approximately one quarter of the
population, of whom one half had normal levels of LDL-C
and triglycerides. Furthermore, the risk of CHD in those
individuals expressing the isolated low HDL-C phenotype
was 20% higher than in those with normal HDL-C levels.
This was particularly evident in Asian populations in whom
the risk of CHD associated with isolated low HDL-C was
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Figure 2. Adjusted hazard ratios (HRs)
and 95% confidence intervals (CIs) for
coronary heart disease associated with
high-density lipoprotein cholesterol levels
(HDL-C) by region (Asia vs Australia/New
Zealand [ANZ]), sex, and smoking status
(current vs not) from studies included in
the Asia Pacific Cohort Studies Collabora-
tion. Normal HDL-C means normal levels
of HDL-C; isolated, isolated low levels of
HDL-C; and low, low levels of HDL-C and
high LDL-C and/or high triglycerides. The
3 groups are mutually exclusive. P for
regional, sex, and smoking interac-
tion0.016, 0.04, and 0.95, respectively.
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similar to that of individuals exhibiting elevated LDL-C
levels.
In comparison, isolated low HDL-C, but not nonisolated
low HDL-C, was associated with a reduced risk of stroke, an
observation that, to the best of our knowledge, has not been
reported previously. A possible explanation for this anoma-
lous finding is that of competing risks; a greater proportion of
individuals with the isolated low HDL-C phenotype may
have died of CHD, thereby excluding them from those at risk
of having a stroke, relative to those with normal HDL-C. In
contrast, individuals with normal HDL-C may have had
elevated triglycerides or LDL-C and therefore received lipid-
lowering medication (in particular fibrates, given that most of
the included studies predated the use of statins), which would
have reduced the risk of CHD but not stroke.20
A key strength of the present analyses, aside from the large
sample size, which affords a greater opportunity to investi-
gate specific patterns of lipid abnormalities, is the ability to
standardize definitions for dyslipidemia across a large num-
ber of studies. Previous studies have been limited in their
ability to make such comparisons owing to the lack of
uniformity in the cut-point values for low HDL-C. In the
present study, the prevalence of low HDL-C was broadly
compatible between countries, with approximately one quar-
ter to one third of the overall populations being affected.
Singapore and India were exceptions; more than half of the
populations were affected, in agreement with earlier
studies.21,22
Surveys conducted in Asian countries also confirm our
finding that low HDL-C is common, affecting between one
Table 4. Comparison of the Age- and Study-Adjusted Characteristics of Study Participants
According to High-Density Lipoprotein Cholesterol Level by Sex and Ethnicity
HDL-C Level*
Isolated Low
HDL-C†
Low HDL-C High
LDL-C and/or TG
Normal
HDL-C‡
n Mean (SD) n Mean (SD) n Mean (SD)
Asian men
SBP, mm Hg 10 263 124.0 (18.7) 6565 127.1 (19.3) 45 783 126.2 (20.0)
DBP, mm Hg 10 262 78.4 (11.8) 6565 80.7 (11.6) 45 780 79.5 (11.9)
BMI, kg/m2 15 982 24.0 (3.4) 10 029 25.2 (3.2) 64 382 23.0 (3.2)
Waist, cm 11 107 84.3 (9.5) 6614 87.7 (8.6) 38 894 81.1 (9.2)
Smoking, % 8826 49.9 5902 51.8 37 580 50.3
Diabetes mellitus, % 15 962 5.6 10 092 9.9 64 240 4.9
Non-Asian men
SBP, mm Hg 1877 130.1 (18.1) 1939 134.6 (17.8) 9725 132.1 (18.3)
DBP, mm Hg 1881 78.1 (11.4) 1946 81.5 (11.5) 9737 78.2 (11.7)
BMI, kg/m2 1858 26.7 (3.9) 1918 28.2 (3.8) 9620 25.8 (3.7)
Waist, cm 1246 94.1 (11.9) 1305 99.5 (10.8) 6740 92.7 (11.1)
Smoking, % 1871 25 1933 29.9 9691 21.7
Diabetes mellitus, % 1881 5.1 1947 6.3 9781 3.9
Asian women
SBP, mm Hg 17 472 122.3 (21.3) 6827 130.5 (23.2) 36 848 122.8 (21.9)
DBP, mm Hg 17 466 75.5 (11.8) 6826 79.3 (11.9) 36 843 75.5 (12.0)
BMI, kg/m2 25 732 23.7 (3.9) 9307 25.3 (3.8) 58 615 22.5 (3.5)
Waist, cm 17 521 76.4 (10.0) 5625 81.6 (9.7) 37 738 72.5 (9.0)
Smoking, % 13 485 7.0 5731 8.4 28 939 6.6
Diabetes mellitus, % 25 692 4.8 9321 12.9 58 559 3.7
Non-Asian women
SBP, mm Hg 2275 122.7 (19.4) 1632 134.1 (21.3) 11 153 125.2 (20.2)
DBP, mm Hg 2275 71.4 (11.9) 1632 75.8 (12.6) 11 167 71.7 (12.1)
BMI, kg/m2 2238 27.1 (5.9) 1607 28.7 (5.3) 10 981 24.9 (4.6)
Waist, cm 1679 84.6 (14.4) 1145 90.5 (13.4) 7872 79.4 (2.1)
Smoking, % 2268 21.6 1625 25.5 11 106 15.6
Diabetes mellitus, % 2286 3.7 1639 8.2 11 208 2.2
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides;
SBP, systolic blood pressure; DBP, diastolic blood pressure; and BMI, body mass index.
*Groups are mutually exclusive. For men, low HDL-C is 1.03 mmol/L; for women, 1.30 mmol/L.
†In the absence of a high LDL-C or high TG level.
‡Normal HDL-C with or without high LDL-C and/or TG.
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quarter and one half of various populations across Asia. For
example, the 2001 Korea National Health and Nutrition
Examination Survey of 4639 adults indicated that the preva-
lence of low HDL-C (defined as 1.03 mmol/L in both
sexes) was 35% in men and 18% in women.23 Because this
study used the same HDL-C cut point for men and women
rather than the sex-specific values recommended by the
NCEP ATP guidelines, it might have considerably underes-
timated the prevalence of low HDL-C in the female Korean
population. Data from Taiwan showed that approximately
one quarter of the population in 2002 had low HDL-C defined
with sex-specific cut points.24 In contrast, data from Singa-
pore have indicated that up to one half of the adult population
have suboptimal HDL-C levels.25 The high prevalence of low
HDL-C present in these populations may partly explain why
migrant studies have shown that South Asians have between
50% and 200% higher CHD rates compared with European
populations even after adjustment for conventional risk fac-
tors such as smoking, BP, and total cholesterol.26,27 These
results suggest that treatment strategies aiming to increase
HDL-C levels might be particularly important in Asia.
The non-Asian populations in this study show a pattern
similar to that described for the adult population of the United
States. With the use of the National Health and Nutrition
Examination Survey (NHANES) 2003–2004 data, the prev-
alence of low HDL-C was estimated to be 26% and isolated
low HDL-C to be 13%,28 compatible to rates reported for
non-Asians in the present study.
In both non-Asian and Asian populations, a low HDL-C
level was more prevalent in obese individuals and those with
diabetes mellitus. These associations are not unexpected
given the clustering of such risk factors in individuals with
the metabolic syndrome. Studies have shown that among the
nearly 4000 individuals with diabetes mellitus reported in the
Pan-European survey, the prevalence of low HDL-C was
50% higher in those with compared with those without
diabetes mellitus.29 Similarly, the greater propensity for low
HDL-C in some specific populations (eg, Indians versus other
ethnic groups) may be explained in part by their increased
susceptibility to central fat accumulation.30
Although low HDL-C is associated with several rare
genetic diseases, including hypoalphalipoproteinemia, the
cause for isolated low HDL-C at the population level remains
largely unknown, although factors such as low levels of
physical activity, obesity, and avoidance of alcohol are
known to be associated with low HDL-C levels. It is therefore
possible that variations in diet, alcohol consumption, and
physical activity will explain some of the variability between
populations. For example, several studies have demonstrated
heterogeneity in plasma lipid responses to different levels of
dietary fat consumption that may indicate an epigenetic
effect.31,32
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Figure 3. Adjusted hazard ratios (HRs)
and 95% confidence intervals (CIs) for
stroke associated with high-density lipo-
protein cholesterol (HDL-C) levels by
region, sex, and smoking status (current
vs not) from studies included in the Asia
Pacific Cohort Studies Collaboration. ANZ
indicates Australia/New Zealand; Normal
HDL-C, normal levels of HDL-C; isolated,
isolated low levels of HDL-C; and low, low
levels of HDL-C and high LDL-C and/or
high triglycerides. The 3 groups are mutu-
ally exclusive. P for regional, sex, and
smoking interaction0.51, 0.51, and 0.88,
respectively.
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This study has several limitations. First, the ethnic group-
ings we use are crude and do not take into account the
potential variation in genetic differences between Asian
populations; we did not have sufficient data to reliably
characterize the phenotypes of individuals with isolated low
HDL-C by country. Second, given the westernization of
many countries across Asia in recent years and the corre-
sponding increase in the prevalence of factors that negatively
affect HDL-C levels, such as obesity and low levels of
physical activity, the mean population level of HDL-C may
have shifted recently to a greater extent in the Asian cohorts.
Third, a significant proportion of the included studies are
cross-sectional, which precludes examination of the temporal
nature of the association between lipids and risk factors.
Fourth, there will have been both interstudy and intrastudy
measurement errors in the ascertainment of lipid measure-
ments. However, the measurement error is likely to have been
random and present across all studies. There may also have
been some bias introduced by the different methods used to
verify cardiovascular outcomes across the APCSC studies.
Finally, data on apolipoproteins and lipid-lowering therapy
were not routinely recorded in the majority of studies in-
cluded in both the OAC and APCSC, which may have
facilitated a more intricate analysis of the data. For example,
information on the use of cholesterol-lowering drugs was
available in 5% of the entire study population. Statin use is
likely to have been uncommon, given that the baseline year of
recruitment for these studies ranged from 1966 to 1994. It is
possible, however, that LDL-C–lowering therapy, eg, with
fibrates or nicotinic acid, which also increases HDL-C,33
would have been more common in Australia and New
Zealand compared with other countries in the Asia-Pacific
region. However, data from the pan-European Survey suggest
that levels of HDL-C are broadly similar in individuals with
and without lipid-lowering therapy.34
Conclusions
Isolated low level of HDL-C is a phenotype that appears to be
particularly common in Asian populations. Individuals exhib-
iting this form of lipid abnormality are at increased risk of
CHD, but, at the same time, are unlikely to be candidates for
lipid-lowering medication because their levels of triglycer-
ides and LDL-C meet targets proposed by current guidelines.
These regions will potentially benefit from strategies that can
increase levels of HDL-C, such as effective smoking cessa-
tion campaigns and initiatives that result in sustained weight
loss and increases in physical activity at the population level.
Moreover, agents such as niacin and fibrates may be partic-
ularly important in Asia. Furthermore, going forward, new
drugs such as cholesteryl ester transfer protein inhibitors may
be important in cardiovascular prevention in the region.
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CLINICAL PERSPECTIVE
This study, comprising information from 220 000 individuals from the Asia-Pacific region, describes a novel and
potentially important form of dyslipidemia. Low levels of high-density lipoprotein cholesterol (HDL-C) have been
independently associated with increased cardiovascular risk. Some earlier observational studies have suggested the
existence of such a distinct type of dyslipidemia with low HDL-C occurring in the absence of elevated levels of other lipid
fractions, ie, isolated low HDL-C. This phenotype has been postulated to be especially prevalent among Asian populations.
Individuals with this form of lipid abnormality are usually not considered to be candidates for lipid-lowering medication
because of their comparatively normal levels of total and low-density lipoprotein cholesterol. This study compared the
prevalence of isolated low HDL-C in Asian and non-Asian populations and determined whether the risk of coronary heart
disease and stroke was elevated in individuals with this form of lipid abnormality. Findings from this study indicated a
substantially higher prevalence of isolated low HDL-C among Asians (22.4%) compared with non-Asians (14.5%) that was
unlikely to be explained by differences in the background rates of lipid-lowering medication, cigarette smoking, and
alcohol use. Both nonisolated low HDL-C and isolated low HDL-C were associated with increased risk of coronary heart
disease but not stroke. Compared with non-Asians, the relationship between isolated low HDL-C and subsequent risk of
coronary heart disease was stronger in Asians. In this group, it was associated with the same magnitude of coronary risk
(60%) as low levels of HDL-C combined with other lipid abnormalities.
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  not-­‐current	  smoker	  (1b;	  n	  =70769)	  	  	  
	  
Supplemental	  Figures	  2a	  and	  b	  Prevalence	  of	  lipid	  phenotypes	  in	  adult	  non-­‐Asians	  who	  reported	  being	  a	  current	  cigarette	  smoker	  at	  study	  baseline	  	  (2a;	  n	  =5776)	  or	  a	  not-­‐current	  smoker	  (2b;	  n	  =22718)	  	  	  
Supplemental	  Table	  1.	  Frequency	  (%)	  and	  95%	  confidence	  intervals	  of	  HDL-­‐cholesterol	  phenotypes	  by	  country	  of	  study	  	   HDL-­‐cholesterol	  level*	  Country	   N	  (%	  female)	   Mean	  age	  (SD)	   Isolated	  low	  HDL-­‐c**	   Low	  HDL-­‐c	  +	  High	  LDL-­‐c	  and/or	  TG	  
Normal	  HDL-­‐c***	  
Australia	   28447	  (52.7)	   48.3	  (15.4)	   14.4	  (14.0-­‐14.8)	   12.5	  (21.1-­‐12.9)	   73.1	  (72.5-­‐73.6)	  China	   66800	  (51.3)	   49.8	  (11.6)	   20.0	  (19.7-­‐20.3)	   8.8	  (8.6-­‐9.0)	   71.2	  (70.9-­‐71.5)	  Hong	  Kong	   1682	  (41.1)	   42.0	  (15.8)	   17.1	  (15.3-­‐18.9)	   8.2	  (6.9-­‐9.5)	   74.8	  (72.7-­‐76.8)	  India	   10026	  (43.0)	   43.7	  (10.4)	   48.9	  (47.9-­‐49.9)	   14.9	  (14.2-­‐15.6)	   36.2	  (35.2-­‐37.1)	  Singapore	   5286	  (51.7)	   39.7	  (12.9)	   26.2	  (25.1-­‐27.4)	   26.9	  (25.7-­‐28.1)	   46.8	  (45.5-­‐48.1)	  South	  Korea	   7944	  (54.9)	   44.7	  (15.8)	   27.9	  (27.0-­‐28.9)	   9.4	  (8.8-­‐10.1)	   62.7	  (61.6-­‐63.7)	  Taiwan	   70084	  (52.7)	   42.9	  (13.6)	   22.2	  (21.9-­‐22.5)	   10.7	  (10.5-­‐10.9)	   67.1	  (66.7-­‐67.4)	  Thailand	   11012	  (41.0)	   47.7	  (10.1)	   18.6	  (17.9-­‐19.4)	   17.6	  (16.9-­‐18.3)	   63.8	  (62.9-­‐64.7)	  Japan	   18779	  (46.7)	   51.5	  (10.5)	   16.3	  (15.8-­‐16.8)	   7.7	  (7.3-­‐8.1)	   76.0	  (75.4-­‐76.6)	  	  
Supplemental	  Table 2a. Hazard ratios (95% confidence intervals) for coronary heart 
disease according to level of high-density lipoprotein cholesterol (HDL-c) defined using 
the modified World Health Organization (WHO) for	  HDL-­‐c	  (<1.0	  in	  men	  and	  <0.9	  mmol/L	  in	  women)	  
Sub-group HDL-c level No. individuals No. events HR (95% CI) 
Asia Normal 47661 202 1.00 (0.82-1.22) 
 Isolated 1759 13 1.10 (0.64-1.88) 
 Low 2269 27 1.20 (0.80-1.80) 
ANZ Normal 16305 300 1.00 (0.87-1.15) 
 Isolated 515 5 0.75 (0.31-1.80) 
 Low 636 27 2.14 (1.47-3.12) 
Male Normal 33613 345 1.00 (0.86-1.16) 
 Isolated 1181 14 0.94 (0.56-1.58) 
 Low 1723 39 1.55 (1.12-2.14) 
Female Normal 30353 157 1.00 (0.78-1.29) 
 Isolated 1093 4 1.24 (0.47-3.30) 
 Low 1182 15 1.81 (1.03-3.19) 
Non-smoking Normal 45344 338 1.00 (0.87-1.15) 
 Isolated 1608 10 0.94 (0.51-1.75) 
 Low 1877 35 1.61 (1.14-2.28) 
Smoking Normal 18622 164 1.00 (0.82-1.21) 
 Isolated 666 8 1.07 (0.54-2.14) 
 Low 1028 19 1.60 (1.01-2.55) 
OVERALL Normal 63966 502 1.00 (0.88 – 1.13) 
 Isolated 2274 18 0.86 (0.57 – 1.29) 
 Low 2905 54 1.02 (0.74 – 1.42) 
 
P value for region interaction = 0.11; for sex interaction = 0.83; for smoking interaction = 
0.97. 
Supplemental Table 2b. Hazard ratios (95% confidence intervals) for coronary heart 
disease according to level of high-density lipoprotein cholesterol (HDL-c) defined using the	  European	  Group	  on	  Insulin	  Resistance	  (EGIR)	  cut-­‐points	  for	  HDL-­‐c	  (<1.0	  mmol/L) 
 
Sub-group HDL-c level No. individuals No. events HR (95% CI) 
Asia Normal 45574 486 1.00 (0.82-1.22) 
 Isolated 2882 31 1.75 (1.22-2.51) 
 Low 3233 48 1.61 (1.15-2.25) 
ANZ Normal 15452 163 1.00 (0.86-1.16) 
 Isolated 933 4 0.67 (0.37-1.20) 
 Low 1071 7 1.77 (1.29-2.43) 
Male Normal 30673 368 1.00 (0.87-1.14) 
 Isolated 2722 30 1.20 (0.86-1.66) 
 Low 3122 34 1.64 (1.27-2.12) 
Female Normal 30353 281 1.00 (0.78-1.29) 
 Isolated 1093 5 1.24 (0.47-3.30) 
 Low 1182 21 1.81 (1.03-3.19) 
Non-smoking Normal 43821 438 1.00 (0.88-1.13) 
 Isolated 2452 22 0.79 (0.52-1.20) 
 Low 2556 36 0.95 (0.67-1.34) 
Smoking Normal 17205 211 1.00 (0.86-1.17) 
 Isolated 1363 13 0.64 (0.36-1.13) 
 Low 1748 19 1.17 (0.73-1.85) 
OVERALL Normal 61026 649 1.00 (0.89 – 1.13) 
 Isolated 3815 35 1.20 (0.88-1.64) 
 Low 4304 55 1.67 (1.32-2.11) 
 
P value for region interaction = 0.027; for sex interaction = 0.96; for smoking interaction 
= 0.53. 
Supplemental Table 3 Hazard ratios (95% confidence intervals) for coronary heart 
disease and stroke associated with isolated low high-density lipoprotein cholesterol 
(HDL-c) before and after adjustment for LDL-cholesterol (LDL-c) and triglycerides (TG) 
 
 Coronary heart disease Stroke 
 Hazard ratio (95% CI) 
Sub-group Adjusted for Adjusted for 
LDL-c and TG 
Current Adjusted for 
LDL-c and TG 
Asia 1.67 (1.27-2.19) 1.72 (1.31-2.26) 0.82 (0.65-1.02) 0.81 (0.65-1.01) 
ANZ 0.79 (0.54-1.14) 0.84 (0.58-1.23) 0.84 (0.51-1.38) 0.83 (0.50-1.36) 
Male 1.30 (1.01-1.67) 1.37 (1.06-1.77) 0.77 (0.58-1.02) 0.76 (0.58-1.01) 
Female 0.91 (0.58-1.43) 0.97 (0.61-1.54) 0.87 (0.65-1.17) 0.87 (0.65-1.16) 
Non-smoking 1.16 (0.88-1.52) 1.23 (0.93-1.62) 0.79 (0.61-1.01) 0.80 (0.63-1.03) 
Smoking 1.24 (0.85-1.81) 1.28 (0.87-1.88) 0.88 (0.62-1.26) 0.88 (0.61-1.26) 
Overall 1.17 (0.95-1.46) 1.25 (0.99-1.56) 0.95 (0.78-1.17) 0.81 (0.66-0.99) 
 
Supplemental Table 4a. Hazard ratios (95% confidence intervals) for stroke according to 
level of high-density lipoprotein cholesterol (HDL-c) defined using the modified World 
Health Organization (WHO) for	  HDL-­‐c	  (<1.0	  in	  men	  and	  <0.9	  mmol/L	  in	  women)	  
 
Sub-group HDL-c level No. individuals No. events HR (95% CI) 
Asia Normal 47661 506 1.00 (0.87-1.15) 
 Isolated 1759 21 0.88 (0.58-1.34) 
 Low 2269 38 1.11 (0.79-1.56) 
ANZ Normal 16305 169 1.00 (0.81-1.24) 
 Isolated 515 2 0.77 (0.19-3.08) 
 Low 636 3 0.58 (0.19-1.80) 
Hemorrhagic Normal 63966 175 1.00 (0.80-1.25) 
 Isolated 2274 4 0.61 (0.23-1.62) 
 Low 2905 7 0.93 (0.43-1.99) 
Ischemic Normal 63966 231 1.00 (0.82-1.22) 
 Isolated 2274 6 0.69 (0.31-1.54) 
 Low 2905 16 1.30 (0.77-2.21) 
Male Normal 33613 345 1.00 (0.85-1.17) 
 Isolated 1181 14 1.12 (0.71-1.77) 
 Low 1723 39 0.92 (0.59-1.46) 
Female Normal 30353 157 1.00 (0.82-1.22) 
 Isolated 1093 4 0.47 (0.20-1.13) 
 Low 1182 15 1.15 (0.72-1.81) 
Non-smoking Normal 45344 338 1.00 (0.87-1.16) 
 Isolated 1608 10 0.76 (0.44-1.31) 
 Low 1877 35 0.93 (0.63-1.38) 
Smoking Normal 18622 164 1.00 (0.84-1.18) 
 Isolated 666 8 1.04 (0.56-1.94) 
 Low 1028 19 1.24 (0.73-2.13) 
OVERALL Normal 63966 675 1.00 (0.88 – 1.13) 
 Isolated 2274 23 0.86 (0.57 – 1.29) 
 Low 2905 41 1.02 (0.74 – 1.42) 
 
P value for region interaction = 0.57; for sex interaction = 0.19; for smoking interaction = 
0.56. 
 
Supplemental Table 4b. Hazard ratios (95% confidence intervals) for stroke according to 
level of high-density lipoprotein cholesterol (HDL-c) defined using the	  European	  Group	  on	  Insulin	  Resistance	  (EGIR)	  cut-­‐points	  for	  HDL-­‐c	  (<1.0	  mmol/L) 
 
Sub-group HDL-c level No. individuals No. events HR (95% CI) 
Asia Normal 45574 486 1.00 (0.88-1.14) 
 Isolated 2882 31 0.78 (0.55-1.11) 
 Low 3233 48 1.04 (0.76-1.41) 
ANZ Normal 15452 163 1.00 (0.81-1.23) 
 Isolated 933 4 0.53 (0.20-1.43) 
 Low 1071 7 0.73 (0.35-1.54) 
Hemorrhagic Normal 61026 171 1.00 (0.81-1.24) 
 Isolated 3815 8 0.66 (0.33-1.33) 
 Low 4304 7 0.65 (0.30-1.39) 
Ischemic Normal 61026 225 1.00 (0.83-1.20) 
 Isolated 3815 11 0.75 (0.42-1.35) 
 Low 4304 17 0.98 (0.59-1.64) 
Male Normal 30673 368 1.00 (0.87-1.15) 
 Isolated 2722 30 0.81 (0.57-1.17) 
 Low 3122 34 0.89 (0.62-1.27) 
Female Normal 30353 281 1.00 (0.82-1.22) 
 Isolated 1093 5 0.47 (0.20-1.13) 
 Low 1182 21 1.15 (0.72-1.82) 
Non-smoking Normal 43821 438 1.00 (0.88-1.13) 
 Isolated 2452 22 0.79 (0.52-1.20) 
 Low 2556 36 0.92 (0.65-1.30) 
Smoking Normal 17205 211 1.00 (0.86-1.16) 
 Isolated 1363 13 0.66 (0.36-1.16) 
 Low 1748 19 1.10 (0.69-1.75) 
OVERALL Normal 61026 649 1.00 (0.89 – 1.12) 
 Isolated 3815 35 0.74 (0.53 – 1.03) 
 Low 4304 55 0.97 (0.73 – 1.29) 
 
P-value for regional interaction = 0.58; for sex interaction = 0.37; for smoking interaction 
= 0.73. 
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summary
배경
과거 연구 결과에 의하면, 관동맥질환 발생 위험과 연관
되어 HDL-C 단독 저하 이상지혈증이 있는 것으로 나타났
으며, 이는 특히 아시아인에서 그 빈도 수가 높은 것으로 
알려져 있다.
방법 및 결과
아시아-태평양 지역 37개 연구 자료를 통해, 총 220,060
명의 참가자(87% 아시아인)를 대상으로 하였으며, 그 중 
HDL-C(HDL-cholesterol) 저하증(남성, HDL <1.03mmol/L; 
여성, HDL <1.30mmol/L)을 보인 경우는 아시아인에서 
33.1%(95% CI, 32.9–33.3), 비아시아인에서는 27.0%(95% 
CI, 26.5–27.5)이었다(P<0.001). HDL-C 단독 저하증을 보
인 경우는 14.5%인 비아시아인(95% CI, 14.1–14.9)에 비
하여 아시아인에서 22.4%(95% CI, 22.2–22.5)로 그 빈도
가 유의하게 높은 것으로 나타났다(P<0.001). 6.8년 추적
기간 동안 574명에서 관동맥질환, 그리고 739명에서 뇌
졸중이 발생하였다. 모든 사람에서 HDL-C 저하증은 관동
맥질환 발생과 역의 상관관계를 보였으며(HR, 1.57; 95% 
CI, 1.31–1.87), 아시아인에서 HDL-C 단독 저하증은 다른 
지질 이상을 동반한 HDL-C 저하증과 마찬가지로 관동맥
질환 발생 위험을 높이는 것으로 나타났다[HR, 1.67(95% 
CI, 1.27–2.19) vs. 1.63(95% CI, 1.24–2.15), respectively]. 
반면에, 본 연구 대상에서는 HDL-C 저하증이 뇌졸중 발
생 위험을 증가시키지 않는 것으로 나타났다.
결론
HDL-C 단독 저하증은 아시안인에서 많이 볼 수 있는 새
로운 이상 지질 표현형으로 관동맥질환 발생 위험을 증가
시키는 것으로 나타났다. 향후 이러한 이상지혈증에 대한 
더 많은 연구가 필요할 것으로 사료된다.
아시아인에서 많은 HDL-C 단독 저하증,  
관동맥질환 발생 위험을 증가시킨다
권	준	교수	인하대병원 심장내과
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commentary
HDL-C 저하증이 LDL-C 수치와 관계없이 관동맥질
환 발생의 독립적인 위험인자라는 것은 잘 알려진 사
실이다. 더구나 몇몇 연구 결과에서는 LDL-C, 그리고 
TG(triglyceride) 수치가 정상치임에도 불구하고 HDL-C 
수치가 단독으로 저하된 경우 LDL-C 수치가 상승한 것
과 같은 정도의 관동맥질환 발생 위험을 가진 것으로 
나타났다. 조사연구 결과, LDL-C나 TG 수치와 관계없이 
HDL-C 수치가 저하된 경우는 나라와 인종에 따라 그 빈
도가 6-34%로 다양하게 나타났다. 그러나 이러한 HDL-C 
저하증에서 HDL-C 수치 상승 치료가 결과적으로 심혈관
질환 발생 위험을 줄일 수 있는지에 대한 임상적 근거는 
아직 부족하다.
본 연구는 과연 아시아인에서 HDL-C 저하증의 빈도가 
높은지 알아보고자 아시아-태평양 지역에서의 2개의 전
향적 코호트(Asia Pacific Cohort Studies Collaboration, 
APCSC) 그리고 횡단적 연구(Obesity in Asia Collaboration, 
OAC)의 자료들을 이용하여 이 지역에서 아시아인과 비
아시아인 분류에 따른 HDL-C 단독 저하증의 빈도를 비
교 분석하였으며, 과연 이것이 관동맥질환과 뇌졸중 발
생 위험 증가와 독립적인 연관성을 가지고 있는지를 조
사하였다. 자료는 중국, 홍콩, 인도, 일본, 한국, 필리핀, 싱
가포르, 대만 그리고 태국에서 얻어진 아시아인 자료 그
리고 호주와 뉴질랜드에서 얻어진 비아시아인 자료로 분
류되었다. 결과적으로, APCSC에서는 총 24개 연구에서 
69,145명, 그리고 OAC에서는 13개 연구에서 총 150,915
명의 자료가 수집되었으며, 이 중 남성의 87%, 그리고 여
성의 86%가 아시아인이었다. 조사 결과 아시아인에서는 
33%에서 HDL-C 저하를 보였으며, HDL-C 단독 저하를 보
인 경우는 27%나 되었다. 반면에, 비아시아인에서는 27%
에서 HDL-C 저하를, 14%에서 HDL-C 단독 저하를 보였
다. LDL-C 상승도 아시아인에서 약 2배 높게 나타났으며, 
반면 TG 상승은 두 인종 간 유의한 차이를 보이지 않았
다. 6.8년 동안의 추적관찰 결과에서 HDL-C 단독 저하증
은 HDL-C 비단독 저하증과 마찬가지로 관동맥질환 발생 
위험을 높이는 것으로 나타났다. 그러나 HDL-C의 단독 
저하증에서는 HDL-C 비단독 저하증과는 달리 뇌졸중 발
생 위험을 전혀 증가시키지 않는 것으로 나타났는데, 이
러한 결과는 이전에 한 번도 보고된 바 없는 매우 흥미로
운 결과이다.
본 연구는 지금까지 진행되어 온 아태 지역에서 이상지혈
증의 형태를 관찰해온 연구 결과 중 최대 규모의 연구 결
과이다. 이번 연구 결과에서도 과거에 관찰되어 왔던 대
로 HDL-C 단독 저하증은 특히 아시아인에서 빈도가 높
은 것으로 나타났다. 그동안 HDL-C 단독 저하증은 LDL-C 
수치와 TG 수치가 정상범주이기 때문에, 약물치료 대상
에서는 제외되어 왔다. 그러나 이번 연구 결과에서 아시
아인에서 HDL-C 단독 저하증 역시 HDL-C 비단독 저하증 
못지않게 관동맥질환 발생 위험을 증가시키는 것으로 나
타났다. 따라서 본 연구 결과는 HDL-C 단독 저하증 환자
들에서의 비약물적 또는 약물적 치료를 통한 HDL-C 상
승효과 대한 임상적 의의를 제시해준 결과라 할 수 있다.
그러나 이번 연구 결과를 해석하는데 짚고 넘어가야 할 
사항이 있다. 그것은 이번 연구 결과에서 아시아인을 국
가별로 세분하여 분석해봤을 때, 특히 싱가포르와 인
도에서의 HDL-C 저하증의 빈도는 50%로 다른 아시
아 국가와 비교해서도 현저히 높다는 것이다. 이는 과거 
INTERHEART 연구1 결과를 바탕으로 한 분석에서도 나타
난 결과이다. 그 당시 타 아시아인에 비해 인도를 포함한 
남아시아인에서 HDL-C, LDL-C 수치가 현저히 낮은 것으
로 나타났다. 남아시아인이 타 인종에 비하여 현저히 높
은 심혈관질환의 발생 위험을 가지고 있는 것은 남아시아
인 패러독스(paradox)로도 잘 알려져 있다. Heng DM 등2
의 보고에 의하면 싱가포르의 심혈관 코호트 연구 결과, 
허혈성 심장질환의 발생률은 싱가포르 거주 인도인에서 
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가장 높았으며, 연령을 보정한 경우 중국인에 비해 남자
에서 2.78배, 여자에서 1.97배 더 높은 것으로 나타났다. 
물론 타 인종에 비해 남아시아인에서 기존의 일반적인 위
험인자(제2형 당뇨병, 고인슐린혈증, 인슐린 저항성, 대사
증후군)의 발생 빈도가 높긴 하다. 그러나 이러한 위험인
자 만으로는 남아시아인에서의 높은 심혈관질환 발생 빈
도를 다 설명할 수 없으며, 본 연구 결과에서도 나타난 남
아시아인에서의 현저한 HDL-C 저하증과 같은 이상지혈
증과 깊은 관련이 있을 것으로 판단된다. 이와 같이 아시
아인 내에서도 남아시아인은 타 아시아인과 달리 심혈관
질환 발생위험뿐 아니라, 이상지혈증의 빈도에서도 역시 
현저한 차이를 보이고 있다. 따라서 이렇게 임상적으로 
그리고 지혈 측정치에서 현저한 차이를 보이는 남아시아
인과 다른 아시아인을 하나의 아시아인으로 묶어 분석하
는 것이 정작 모든 아시아인에게 적용할 수 있는 효과적
인 치료 가이드라인을 결정하는 데 올바른 정보를 줄 것
인지 의구심이 든다. 아마도 이를 위해서는 향후 아시아
인을 남아시아인과 비남아시아인으로 구분하여 이에 따
른 이상지혈증의 빈도와 심혈관질환 발생 위험을 비교 
분석하는 연구가 더 있어야 할 것으로 사료된다. 
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Isolated Low Levels of High-Density Lipoprotein Cholesterol
Are Associated With an Increased Risk of Coronary
Heart Disease
An Individual Participant Data Meta-Analysis of 23 Studies in the
Asia-Pacific Region
Rachel R. Huxley, DPhil; Federica Barzi, PhD; Tai Hing Lam, MD; Sebastien Czernichow, PhD;
Xianghua Fang, PhD; Tim Welborn, PhD; Jonathan Shaw, MD; Hirotsugu Ueshima, MD;
Paul Zimmet, PhD; Sun Ha Jee, PhD; Jeetesh V. Patel, MD; Ian Caterson, PhD;
Vlado Perkovic, PhD; Mark Woodward, PhD; for the Asia Pacific Cohort Studies Collaboration and the
Obesity in Asia Collaboration
Background—Previous studies have suggested that there is a novel dyslipidemic profile consisting of isolated low
high-density lipoprotein cholesterol (HDL-C) level that is associated with increased risk of coronary heart disease, and
that this trait may be especially prevalent in Asian populations.
Methods and Results—Individual participant data from 220 060 participants (87% Asian) in 37 studies from the
Asia-Pacific region were included. Low HDL-C (HDL �1.03 mmol/L in men and �1.30 mmol/L in women) was seen
among 33.1% (95% confidence interval [CI], 32.9–33.3) of Asians versus 27.0% (95% CI, 26.5–27.5) of non-Asians
(P�0.001). The prevalence of low HDL-C in the absence of other lipid abnormalities (isolated low HDL-C) was higher
in Asians compared with non-Asians: 22.4% (95% CI, 22.2–22.5) versus 14.5% (95% CI, 14.1–14.9), respectively
(P�0.001). During 6.8 years of follow-up, there were 574 coronary heart disease and 739 stroke events. There was an
inverse relationship between low HDL-C with coronary heart disease in all individuals (hazard ratio, 1.57; 95% CI,
1.31–1.87). In Asians, isolated low levels of HDL-C were as strongly associated with coronary heart disease risk as low
levels of HDL-C combined with other lipid abnormalities (hazard ratio, 1.67 [95% CI, 1.27–2.19] versus 1.63 [95% CI,
1.24–2.15], respectively). There was no association between low HDL-C and stroke risk in this population (hazard ratio,
0.95 [95% CI, 0.78 to 1.17] with nonisolated low HDL-C and 0.81 [95% CI, 0.67–1.00] with isolated low HDL-C).
Conclusion—Isolated low HDL-C is a novel lipid phenotype that appears to be more prevalent among Asian
populations, in whom it is associated with increased coronary risk. Further investigation into this type of
dyslipidemia is warranted. (Circulation. 2011;124:2056-2064.)
Key Words: cardiovascular diseases � cholesterol � epidemiology
The direct but opposing relationships of low-density lipo-protein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) with coronary heart disease (CHD) risk
are well characterized in many populations.1–3 There is also
increasing recognition of the importance of HDL-C in deter-
mining coronary risk independently of LDL-C levels.4,5
Moreover, some studies suggest that isolated low HDL-C, a
condition that describes the coexistence of low HDL-C in
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conjunction with normal LDL-C and triglyceride levels, has
a coronary risk equivalent to that of elevated LDL-C.6–8
Clinical Perspective on p??6
Survey data suggest that the prevalence of low HDL-C,
either in isolation or in conjunction with abnormal LDL-C or
triglyceride levels, differs substantially between countries and
ethnic groups, and published values for the prevalence of
isolated low HDL-C range from 6% to 34%.6,9–11 However,
individuals with this lipid phenotype are unlikely to be
considered for pharmacotherapy partly because their LDL-C
and total cholesterol levels fall within current guidelines, and
partly because there is insufficient randomized evidence
unequivocally demonstrating that raising HDL-C levels re-
duces cardiovascular risk.12
Here, we determine whether isolated low HDL-C is a form
of dyslipidemia that occurs more frequently in Asian popu-
lations using data from 2 large-scale collaborations of pro-
spective cohorts and cross-sectional studies from the Asia-
Pacific region, namely the Asia Pacific Cohort Studies
Collaboration (APCSC) and the Obesity in Asia Collabora-
tion (OAC). We also examine whether isolated low HDL-C is
independently associated with increased risk of CHD and stroke
and if there is a particular phenotype associated with low HDL-C
based on routinely measured clinical characteristics.
Methods
Asia Pacific Cohort Studies Collaboration
Details of APCSC, including study identification, data collection,
and event verification, are given elsewhere.13,14 All studies included
in APCSC were conducted prospectively in populations from the
Asia-Pacific region, had at least 5000 person-years of follow-up, and
recorded age, sex, and blood pressure (BP) at baseline, as well as
vital status at the end of the follow-up. Lipid measurements were
determined with serum samples, which were obtained while fasting
in �93% of participants. Information regarding the method of
cholesterol analysis was available for �70% of all participants, of
whom 96% used enzymatic methods. Most studies additionally
recorded current smoking status (current/not current) at baseline. BP
was measured at rest in the seated position with a standard mercury
sphygmomanometer in most studies.
Obesity in Asia Collaboration
Details of OAC, including study identification, data collection, and
event verification, are given elsewhere.15,16 Studies were eligible if
they contained information on age, sex, weight, height, waist
circumference, hip circumference, fasting plasma glucose, and BP
and measures on at least 1 lipid variable (total cholesterol, HDL-C,
LDL-C, or triglycerides).
All of the included studies from both the APCSC and OAC were
classified as Asian if study members were recruited from mainland
China, Hong Kong, India, Japan, Korea, the Philippines, Singapore,
South Korea, Taiwan, or Thailand; they were classified as Australia/
New Zealand if participants were drawn from Australia or New
Zealand. This classification largely represented a split by ethnicity
into Asians and non-Asians.
Statistical Methods
Participants without information on lipids were excluded from these
analyses. When not measured directly, LDL-C was calculated from
the Friedewald formula in samples in which triglyceride levels were
�400 mg/dL.17 National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) guidelines were
used to identify people with low values of HDL-C (�1.03 mmol/L
in men, �1.30 mmol/L in women), high values of LDL-C
(�4.14 mmol/L), and high values of triglycerides (�2.26 mmol/L).18
These guidelines were chosen to facilitate comparisons with previous
work. Venn diagrams were constructed to illustrate the frequency of
different forms of dyslipidemia within Asians and non-Asians.
Because cigarette smoking is negatively associated with HDL-C
levels, the frequency of lipid abnormalities was also examined by
smoking status separately within Asia and Australia/New Zealand.
The outcomes analyzed in this study were fatal or nonfatal CHD
(International Classification of Disease codes 410, 411, 412, 413,
414, and 798) and stroke (codes 430–438). Fatal CHD and stroke
events were recorded in 37 studies from the APCSC using a variety
of methods, most often through death registrations or personal
contact with subjects or relatives. Nonfatal events were recorded in
8 studies through hospital records or personal contact. The median
follow-up was 6.6 years in Asia and 8.3 years in non-Asian
countries.
Individuals were divided into 3 mutually exclusive groups accord-
ing to lipid levels: normal HDL-C, isolated low HDL-C, and
nonisolated low HDL-C (ie, low HDL-C combined with elevated
LDL-C and/or triglycerides). Differences in the distribution of BP
and anthropometry across these groups were assessed with general
linear models, and differences in the percentages of smoking and
diabetes mellitus were assessed with logistic regression models. All
models accounted for the confounding effects of age and study.
Hazard ratios (HRs) for CHD and stroke events were calculated with
Cox proportional hazard models, with corresponding 95% confi-
dence intervals (CIs) derived with floating absolute risks and taking
those with normal HDL-C as the reference group. The continuous
relationships between HDL-C and cardiovascular outcomes are
described in detail elsewhere.4 In the main analysis, Cox models
were adjusted by age, systolic BP, and current smoking and stratified
by study and sex. A sensitivity analysis was performed comparing
current smokers with not-current smokers separately within Asia and
Australia/New Zealand in models adjusted for age and systolic BP
and stratified by study and sex. In a subgroup of the population
(n�64 310), information on alcohol consumption at study baseline
was available (yes/no); among this group, the models were rerun
stratifying by alcohol status. In secondary analyses, we examined the
relationships with cardiovascular outcomes when low HDL-C level
was defined according to the modified World Health Organization
(WHO) guidelines (�1.0 mmol/L in men and �0.9 mmol/L in
women) and the European Group for Insulin Resistance (EGIR)
guidelines (�1.0 mmol/L).19
All analyses were conducted with SAS version 9.1 (SAS Institute,
Inc, Cary, NC).
Results
Information was available on 69 145 eligible study partici-
pants from 24 studies from the APCSC (Table 1) and 150 915
from 13 studies in the OAC (Table 2). Overall, 87% of men
and 86% of women were from Asia. The overall mean levels
of cardiovascular risk factors for Asians and non-Asians are
summarized in Table 3.
In the Asian cohorts, one third (33%) displayed low levels
of HDL-C (n�63 316), and two thirds of these individuals
(22% overall) had isolated levels of low HDL-C (Figure 1A).
These estimates were comparable in current (Figure Ia in the
online-only Data Supplement) and not-current (Figure Ib in
the online-only Data Supplement) smokers. High levels of
LDL-C either with or without other colipid abnormalities
occurred in 13% of the population. When examined by
country, the frequency of low HDL-C varied between one
quarter and one third of the study population, with the notable
exceptions of Singapore and India, where �50% of the
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population was affected (Table I in the online-only Data
Supplement).
In non-Asians, 27% of individuals (n�7754) had low
levels of HDL-C either with or without associated colipid
abnormalities. Isolated low HDL-C occurred in half of these
individuals (n�4021, 14% of non-Asians; Figure 1B). These
estimates were similar in current and not-current smokers
(Figure IIa and IIb in the online-only Data Supplement,
Table 1. Baseline Study Characteristics of Contributing Studies From the Asia Pacific Cohort Studies Collaboration
Cohort Country n
Age,
y
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
LDL-C,
mmol/L
BMI,
kg/m2
SBP,
mm Hg
Smoking,
%
Diabetes
Mellitus,
% WC, cm
Hip
Circumference,
cm
Obesity,*
%
ALSA Australia 1121 78 (6) 5.8 (1.1) 1.5 (0.7) 1.3 (0.4) 3.8 (1.0) 25.7 (3.9) 149 (22) 8.3 7.1 . . . . . . 13.0
ANHF Australia 8924 43 (13) 5.5 (1.1) 1.4 (0.7) 1.3 (0.4) 3.5 (1.0) 25.3 (4.2) 126 (18) 23.8 1.7 83 (13) 100 (9) 12.2
Busselton Australia 1585 44 (17) 5.7 (1.2) 1.2 (0.7) 1.5 (0.4) 3.6 (1.1) 24.6 (3.7) 129 (20) 24.0 7.3 . . . . . . 8.0
Perth Australia 5826 45 (13) 5.6 (1.1) 1.2 (0.7) 1.4 (0.4) 3.7 (1.0) 25.5 (4.2) 130 (21) 25.4 2.5 . . . . . . 13.2
Aito town Japan 893 52 (7) 4.7 (0.8) 1.3 (0.4) 1.4 (0.4) 2.6 (0.8) 22.6 (3.0) 139 (20) 30.8 1.7 . . . . . . 4.5
Akabane Japan 1819 54 (8) 5.0 (0.9) 1.2 (0.7) 1.2 (0.3) 3.2 (0.8) 22.5 (3.0) 125 (19) 27.8 2.4 . . . . . . 4.1
Anzhen02 China 4078 47 (8) 4.7 (0.9) 1.2 (0.7) 1.4 (0.4) 2.7 (0.8) 24.0 (3.3) 122 (18) 20.6 10.7 80 (9) 97 (7) 11.1
Beijing Aging China 1675 69 (8) 4.4 (1.0) 1.5 (0.8) 1.5 (0.6) 3.0 (1.0) 23.3 (3.9) 141 (25) 30.6 29.4 . . . . . . 11.4
CISC China 164 45 (9) 5.0 (0.8) 0.7 (0.6) 1.1 (0.3) 2.8 (1.2) 22.9 (2.7) 123 (20) 73.6 . . . . . . 4.3
Civil Service
Workers
Japan 8910 47 (5) 5.2 (0.9) 1.4 (0.8) 1.4 (0.4) 3.1 (0.8) 22.4 (2.7) 125 (18) 37.8 1.7 . . . . . . 3.0
CVDFACTS China 460 45 (16) 4.8 (1.0) 1.2 (0.7) 1.3 (0.4) 3.0 (0.9) 23.2 (3.4) 113 (19) 22.4 3.0 . . . . . . 8.1
EGAT Thailand 3390 43 (5) 5.7 (1.1) 1.6 (0.8) 1.2 (0.3) 3.8 (1.0) 23.0 (3.1) 120 (16) 43.0 2.5 . . . . . . 6.6
Fangshan China 774 47 (9) 4.6 (1.0) 1.5 (0.7) 1.4 (0.4) 2.5 (0.9) 24.9 (3.6) 132 (25) 38.4 6.3 . . . . . . 18.9
Guangzhou
Occupational
China 9106 43 (6) 5.2 (1.0) 1.4 (0.7) 1.3 (0.5) 3.3 (1.1) 22.6 (3.3) 113 (15) 44.4 7.9 . . . . . . 7.6
Hong Kong Hong Kong 183 79 (7) 5.2 (0.9) 1.6 (1.0) 1.5 (0.5) 3.0 (0.8) 22.0 (3.6) 148 (22) 16.9 10.4 81 (10) 91 (8) 7.3
Huashan China 1744 53 (12) 4.6 (0.9) 1.4 (0.7) 1.4 (0.4) 2.6 (0.8) 23.3 (3.4) 126 (21) . . . 10.6 . . . . . . 8.6
Konan Japan 1206 52 (16) 4.9 (0.9) 1.1 (0.6) 1.6 (0.4) 2.8 (0.8) 21.9 (3.0) 130 (19) 29.7 12.6 . . . . . . 3.2
Miyama Japan 404 59 (9) 5.1 (0.9) 1.2 (0.6) 1.3 (0.3) 3.2 (0.8) 22.3 (3.0) 129 (23) 23.6 2.2 . . . . . . 4.2
Ohasama Japan 1869 58 (11) 5.0 (0.9) 1.5 (0.8) 1.4 (0.4) 2.9 (0.8) 23.2 (3.1) 127 (17) 20.1 9.2 . . . . . . 7.3
Seven Cities
Cohorts
China 6050 58 (10) 4.9 (1.3) 1.6 (0.7) 1.5 (0.5) 2.7 (1.3) 22.9 (3.8) 134 (25) 33.9 1.6 . . . . . . 9.9
Shigaraki Town Japan 3678 57 (14) 5.0 (0.9) 1.4 (0.7) 1.5 (0.4) 2.9 (0.8) 22.5 (3.1) 132 (20) 28.5 7.1 . . . . . . 4.8
Singapore Heart Singapore 2063 41 (13 5.8 (1.1) 1.3 (0.8) 1.0 (0.3) 4.2 (1.0) 23.5 (4.4) 123 (21) 20.8 10.9 . . . . . . 15.4
Singapore NHS92 Singapore 3223 39 (12) 5.3 (1.0) 1.3 (0.8) 1.3 (0.3) 3.5 (0.9) 23.2 (4.2) 118 (18) 18.0 9.1 . . . . . . 11.6
TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; SBP,
systolic blood pressure; WC, waist circumference; ALSA, Australian Longitudinal Study of Aging; ANHF, Australian National Heart Foundation; CISC, Capital Iron and
Steel Company; CVDFACTS, The Cardiovascular Disease Risk Factors Two-Townships Study; NHS92, National Health Survey 1992; and EGAT, Electricity Generating
Authority of Thailand. Ellipses indicate missing data. Values are mean (SD) unless otherwise specified.
*Obesity was defined as body mass index �30 kg/m2 in non-Asians and �28 kg/m2 in Asians.
Table 2. Baseline Study Characteristics of Contributing Studies From the Obesity in Asia Collaboration
Cohort Country n
Age,
y
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
LDL-C,
mmol/L
BMI,
kg/m2
SBP,
mm Hg
Smoking,
%
Diabetes
Mellitus,
%
WC,
cm
Hip
Circumference,
cm
Obesity,
%
AUSDIAB Australia 10 991 52 (15) 5.6 (1.0) 1.5 (0.8) 1.4 (0.4) 3.5 (0.9) 26.9 (4.9) 129 (19) 15.6 5.1 91 (14) 105 (10) 21.7
China (Zhou) China 43 209 49 (12) 4.7 (1.0) 1.3 (0.7) 1.4 (0.4) 2.7 (0.9) 23.7 (3.6) 126 (22) 29.0 4.8 79 (10) 94 (8) 11.3
EGAT2 Thailand 2746 43 (5) 6.1 (1.1) 1.6 (0.8) 1.5 (0.4) 3.9 (1.1) 23.8 (3.6) 123 (21) 25.8 4.0 84 (10) 96 (7) 11.4
HK (Lam) Hong Kong 1499 37 (9) 5.1 (0.9) 1.1 (0.8) 1.4 (0.4) 3.3 (0.9) 23.3 (3.2) 118 (15) 14.5 2.3 78 (9) 93 (6) 7.3
India (Mohan) India 2422 41 (7) 4.6 (1.1) 1.6 (0.8) 1.0 (0.3) 3.0 (1.1) 23.9 (3.6) 121 (13) 31.7 9.9 87 (10) 90 (7) 11.2
India (Mohan) India 619 48 (9) 5.3 (1.0) 1.5 (1.0) 1.3 (0.4) 3.3 (0.9) 27.0 (4.6) 119 (15) 4.4 2.4 87 (12) 99 (10) 34.0
India (Mohan) India 2300 40 (13) 4.6 (1.0) 1.3 (0.7) 1.1 (0.3) 2.9 (0.8) 22.8 (4.0) 119 (18) 18.5 8.4 83 (11) 94 (9) 8.8
India (Mohan) India 4115 47 (9) 4.8 (1.0) 1.7 (0.7) 1.1 (0.2) 3.0 (0.9) 23.3 (4.9) 119 (20) 20.2 8.5 81 (13) 90 (11) 16.3
India (Lear) India 299 39 (13) 4.4 (1.0) 1.2 (0.7) 1.4 (0.3) 2.5 (0.9) 24.9 (4.3) 114 (14) 5.7 1.4 81 (11) 99 (9) 16.8
India (Patel) India 271 50 (14) 4.9 (1.0) 1.0 (0.5) 1.2 (0.3) 3.3 (0.9) 21.0 (3.9) 116 (22) . . . 7.8 76 (12) 92 (8) 4.8
INTERASIA Thailand 4876 54 (12) 5.4 (1.2) 1.6 (0.8) 1.2 (0.3) 3.5 (1.1) 24.2 (4.4) 122 (20) 20.9 9.4 82 (12) 94 (9) 17.4
KNHANES Korea 7944 45 (16) 4.9 (1.0) 1.4 (0.7) 1.3 (0.3) 2.9 (0.9) 23.2 (3.2) 126 (20) . . . 9.1 80 (9) 93 (7) 7.1
Taiwan Taiwan 69 624 43 (14) 5.2 (1.0) 1.3 (0.7) 1.3 (0.4) 3.3 (0.8) 23.1 (3.4) 128 (23) . . . 3.6 77 (10) 94 (6) 7.9
TC indicates total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; SBP,
systolic blood pressure; WC, waist circumference; AUSDIAB, Australian Diabetes Obesity and Lifestyle Study; EGAT2, Electricity Generating Authority of Thailand 2;
INTERASIA, International Collaborative Study of Cardiovascular Disease in Asia; and KNHANES, Korean National Health and Nutrition Examination Survey. Ellipses
indicate missing data. Values are mean (SD) unless specified otherwise.
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respectively). Overall, the frequency of high LDL-C was
twice as high in Asian as in non-Asian populations (26.1%
[95% CI, 25.6–26.6] versus 13.4% [95% CI, 13.3–13.6];
P�0.001; Figure 2B), whereas the frequency of elevated
triglycerides was comparable between non-Asians and Asians
(12.6% [95% CI, 12.2–13.0] versus 11.6% [95% CI, 11.5–
11.8], respectively, although the P for the regional difference
was �0.0001 because of the large sample size).
Table 4 shows the mean phenotypic characteristics of
individuals with nonisolated low HDL-C, isolated low
HDL-C, and normal levels of HDL-C. Overall, low HDL-C
levels were more associated with higher values of body mass
index and waist circumference and a higher frequency of
diabetes mellitus compared with normal levels of HDL-C,
regardless of sex and region. There were no consistent
associations between BP and smoking status with HDL-C
levels within the sex and region groups.
During a median follow-up of 6.8 years, there were 574
fatal and nonfatal CHD events (42% Asia) and 739 fatal and
nonfatal stroke events (76% Asia). Of these, there were 253
ischemic and 186 hemorrhagic strokes (the remainder were
unclassified). In adjusted analyses, nonisolated low levels of
HDL-C were associated with a nearly 60% higher risk of
CHD compared with normal levels of HDL-C (HR, 1.57;
95% CI, 1.31–1.87). This association was observed in all
individuals regardless of sex, region, and smoking status
(Figure 2). This estimate did not differ materially when either
the WHO or EGIR cut points for HDL-C were used (Table IIa
and IIb in the online-only Data Supplement). In the subgroup
for whom information was available on alcohol consumption
at study baseline (yes/no), there was no evidence of interac-
tion in the association between low levels of HDL-C with
subsequent CHD (HR, 1.55 [ 95% CI, 1.18–2.04] in current
drinkers versus 1.59 [95% CI, 1.26–2.00] in nondrinkers;
Table 3. Summary of the Baseline Characteristics of the Overall Study Participants From the Asia Pacific
Cohort Studies Collaboration and the Obesity in Asia Collaboration
Men Women
Mean (SD) Mean (SD)
Variable n Asian Non-Asian n Asian Non-Asian
Age, y 108 455 46.7 (12.7) 48.5 (15.6) 111 605 46.4 (13.2) 48.1 (15.2)
Total cholesterol, mmol/L 108 455 5.05 (1.03) 5.56 (1.04) 111 605 5.02 (1.03) 5.59 (1.11)
Triglycerides, mmol/L 108 455 1.48 (0.78) 1.51 (0.81) 111 605 1.24 (0.69) 1.26 (0.70)
HDL-C, mmol/L 108 455 1.24 (0.37) 1.24 (0.32) 111 605 1.43 (0.38) 1.53 (0.38)
LDL-C, mmol/L 108 455 3.13 (0.98) 3.64 (0.94) 111 605 3.05 (0.95) 3.49 (0.98)
Body mass index, kg/m2 103 789 23.4 (3.31) 26.3 (3.81) 108 480 23.1 (3.76) 25.7 (5.07)
Waist circumference, cm 65 906 82.5 (9.5) 93.8 (11.5) 71 580 74.5 (9.8) 81.4 (13.1)
SBP, mm Hg 76 152 125.9 (19.5) 132.1 (18.2) 76 207 123.5 (22.0) 125.8 (20.4)
DBP, mm Hg 76 171 78.7 (12.0) 79.4 (10.9) 76 209 75.9 (11.9) 72.1 (11.1)
Smoking, % 65 803 50.4 23.3 63 154 6.9 17.5
Diabetes mellitus, % 103 903 5.6 4.4 108 705 4.9 4.6
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and
DBP, diastolic blood pressure.
Figure 1. A and B, Prevalence of lipid phenotypes in adult Asian populations (A; n�191 317) and adult populations from Australia and
New Zealand (B; n�28 743). HDL indicates high-density lipoprotein; HDL-C, HDL cholesterol; LDL, low-density lipoprotein; and TG,
triglycerides.
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P�0.99). For purposes of comparison, the risk of CHD
associated with LDL-C level was also determined. In this
population, the risk of CHD was nearly 60% higher in those
with high levels of LDL-C compared with those with normal
levels of LDL-C (HR, 1.58; 95% CI, 1.30–1.93).
There was some evidence that isolated low HDL-C in-
creased the risk of incurring a CHD event compared with
normal HDL-C, although the relationship was nonsignificant
(HR, 1.17; 95% CI, 0.95–1.46). This estimate did not alter
materially when the EGIR cut points were used; however,
there was no association when the modified WHO cut points
were used (Table II in the online-only Data Supplement),
although this may have been a chance finding given the small
number of events in those with isolated low HDL-C (n�18).
In sensitivity analyses, the relationship between isolated low
HDL-C and CHD was particularly apparent in Asian cohorts
compared with studies from Australia/New Zealand (HR,
1.67 [95% CI, 1.27–2.19] versus 0.79 [95% CI, 0.54 – 1.14];
P for regional interaction�0.016) and in men compared with
women (HR, 1.30 [95% CI, 1.01–1.67] versus 0.91 [95% CI,
0.58–1.43]; P for sex interaction�0.04). There was no
evidence of an interaction with smoking (P�0.95) or alcohol
(P�0.99). In Asians, isolated low HDL-C was as strongly
associated with CHD risk as nonisolated low levels of
HDL-C (HR, 1.67 [95% CI, 1.27–2.19] versus 1.63 [95% CI,
1.24–2.15], respectively). These results did not differ mate-
rially according to how low HDL-C level was defined (Table
IIa and IIb in the online-only Data Supplement) or after
adjustment for LDL-C and triglycerides (Table III in the
online-only Data Supplement).
In adjusted analyses, nonisolated low HDL-C was not
associated with risk of stroke compared with those individu-
als with normal HDL-C (HR, 0.95; 95% CI, 0.78–1.17), both
in the overall analysis and within any of the subgroups
(Figure 3). This remained unchanged when either the WHO
or EGIR cut points for low HDL-C were used (Table IVa and
IVb in the online-only Data Supplement). Furthermore, there
was no evidence of an interaction between HDL-C level and
alcohol consumption (P�0.70).
In those with isolated low HDL-C, there was an �20%
lower risk of stroke compared with those with normal HDL-C
both in the overall population and within major subgroups
(Figure 3). This remained true regardless of the cut point used
to define low HDL-C (Table IVa and IVb in the online-only
Data Supplement) and remained unchanged after adjustment
for LDL-C and triglycerides (Table III in the online-only
Data Supplement).
Discussion
Data from 2 large collaborations of studies with information
on nearly 220 000 individuals conducted within populations
of the Asia-Pacific region suggest a phenotype of dyslipid-
emia that is highly prevalent, but not unique, to Asian
populations. The most frequent pattern of dyslipidemia
among the Asian population (observed in approximately one
third) was low HDL-C levels. In two thirds of these individ-
uals, low levels of HDL-C occurred in the absence of any
associated colipid abnormality, and this was the most com-
mon individual lipid abnormality. In non-Asians, low levels
of HDL-C were evident in approximately one quarter of the
population, of whom one half had normal levels of LDL-C
and triglycerides. Furthermore, the risk of CHD in those
individuals expressing the isolated low HDL-C phenotype
was 20% higher than in those with normal HDL-C levels.
This was particularly evident in Asian populations in whom
the risk of CHD associated with isolated low HDL-C was
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Figure 2. Adjusted hazard ratios (HRs)
and 95% confidence intervals (CIs) for
coronary heart disease associated with
high-density lipoprotein cholesterol levels
(HDL-C) by region (Asia vs Australia/New
Zealand [ANZ]), sex, and smoking status
(current vs not) from studies included in
the Asia Pacific Cohort Studies Collabora-
tion. Normal HDL-C means normal levels
of HDL-C; isolated, isolated low levels of
HDL-C; and low, low levels of HDL-C and
high LDL-C and/or high triglycerides. The
3 groups are mutually exclusive. P for
regional, sex, and smoking interac-
tion�0.016, 0.04, and 0.95, respectively.
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similar to that of individuals exhibiting elevated LDL-C
levels.
In comparison, isolated low HDL-C, but not nonisolated
low HDL-C, was associated with a reduced risk of stroke, an
observation that, to the best of our knowledge, has not been
reported previously. A possible explanation for this anoma-
lous finding is that of competing risks; a greater proportion of
individuals with the isolated low HDL-C phenotype may
have died of CHD, thereby excluding them from those at risk
of having a stroke, relative to those with normal HDL-C. In
contrast, individuals with normal HDL-C may have had
elevated triglycerides or LDL-C and therefore received lipid-
lowering medication (in particular fibrates, given that most of
the included studies predated the use of statins), which would
have reduced the risk of CHD but not stroke.20
A key strength of the present analyses, aside from the large
sample size, which affords a greater opportunity to investi-
gate specific patterns of lipid abnormalities, is the ability to
standardize definitions for dyslipidemia across a large num-
ber of studies. Previous studies have been limited in their
ability to make such comparisons owing to the lack of
uniformity in the cut-point values for low HDL-C. In the
present study, the prevalence of low HDL-C was broadly
compatible between countries, with approximately one quar-
ter to one third of the overall populations being affected.
Singapore and India were exceptions; more than half of the
populations were affected, in agreement with earlier
studies.21,22
Surveys conducted in Asian countries also confirm our
finding that low HDL-C is common, affecting between one
Table 4. Comparison of the Age- and Study-Adjusted Characteristics of Study Participants
According to High-Density Lipoprotein Cholesterol Level by Sex and Ethnicity
HDL-C Level*
Isolated Low
HDL-C†
Low HDL-C� High
LDL-C and/or TG
Normal
HDL-C‡
n Mean (SD) n Mean (SD) n Mean (SD)
Asian men
SBP, mm Hg 10 263 124.0 (18.7) 6565 127.1 (19.3) 45 783 126.2 (20.0)
DBP, mm Hg 10 262 78.4 (11.8) 6565 80.7 (11.6) 45 780 79.5 (11.9)
BMI, kg/m2 15 982 24.0 (3.4) 10 029 25.2 (3.2) 64 382 23.0 (3.2)
Waist, cm 11 107 84.3 (9.5) 6614 87.7 (8.6) 38 894 81.1 (9.2)
Smoking, % 8826 49.9 5902 51.8 37 580 50.3
Diabetes mellitus, % 15 962 5.6 10 092 9.9 64 240 4.9
Non-Asian men
SBP, mm Hg 1877 130.1 (18.1) 1939 134.6 (17.8) 9725 132.1 (18.3)
DBP, mm Hg 1881 78.1 (11.4) 1946 81.5 (11.5) 9737 78.2 (11.7)
BMI, kg/m2 1858 26.7 (3.9) 1918 28.2 (3.8) 9620 25.8 (3.7)
Waist, cm 1246 94.1 (11.9) 1305 99.5 (10.8) 6740 92.7 (11.1)
Smoking, % 1871 25 1933 29.9 9691 21.7
Diabetes mellitus, % 1881 5.1 1947 6.3 9781 3.9
Asian women
SBP, mm Hg 17 472 122.3 (21.3) 6827 130.5 (23.2) 36 848 122.8 (21.9)
DBP, mm Hg 17 466 75.5 (11.8) 6826 79.3 (11.9) 36 843 75.5 (12.0)
BMI, kg/m2 25 732 23.7 (3.9) 9307 25.3 (3.8) 58 615 22.5 (3.5)
Waist, cm 17 521 76.4 (10.0) 5625 81.6 (9.7) 37 738 72.5 (9.0)
Smoking, % 13 485 7.0 5731 8.4 28 939 6.6
Diabetes mellitus, % 25 692 4.8 9321 12.9 58 559 3.7
Non-Asian women
SBP, mm Hg 2275 122.7 (19.4) 1632 134.1 (21.3) 11 153 125.2 (20.2)
DBP, mm Hg 2275 71.4 (11.9) 1632 75.8 (12.6) 11 167 71.7 (12.1)
BMI, kg/m2 2238 27.1 (5.9) 1607 28.7 (5.3) 10 981 24.9 (4.6)
Waist, cm 1679 84.6 (14.4) 1145 90.5 (13.4) 7872 79.4 (2.1)
Smoking, % 2268 21.6 1625 25.5 11 106 15.6
Diabetes mellitus, % 2286 3.7 1639 8.2 11 208 2.2
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides;
SBP, systolic blood pressure; DBP, diastolic blood pressure; and BMI, body mass index.
*Groups are mutually exclusive. For men, low HDL-C is �1.03 mmol/L; for women, �1.30 mmol/L.
†In the absence of a high LDL-C or high TG level.
‡Normal HDL-C with or without high LDL-C and/or TG.
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quarter and one half of various populations across Asia. For
example, the 2001 Korea National Health and Nutrition
Examination Survey of 4639 adults indicated that the preva-
lence of low HDL-C (defined as �1.03 mmol/L in both
sexes) was 35% in men and 18% in women.23 Because this
study used the same HDL-C cut point for men and women
rather than the sex-specific values recommended by the
NCEP ATP guidelines, it might have considerably underes-
timated the prevalence of low HDL-C in the female Korean
population. Data from Taiwan showed that approximately
one quarter of the population in 2002 had low HDL-C defined
with sex-specific cut points.24 In contrast, data from Singa-
pore have indicated that up to one half of the adult population
have suboptimal HDL-C levels.25 The high prevalence of low
HDL-C present in these populations may partly explain why
migrant studies have shown that South Asians have between
50% and 200% higher CHD rates compared with European
populations even after adjustment for conventional risk fac-
tors such as smoking, BP, and total cholesterol.26,27 These
results suggest that treatment strategies aiming to increase
HDL-C levels might be particularly important in Asia.
The non-Asian populations in this study show a pattern
similar to that described for the adult population of the United
States. With the use of the National Health and Nutrition
Examination Survey (NHANES) 2003–2004 data, the prev-
alence of low HDL-C was estimated to be 26% and isolated
low HDL-C to be 13%,28 compatible to rates reported for
non-Asians in the present study.
In both non-Asian and Asian populations, a low HDL-C
level was more prevalent in obese individuals and those with
diabetes mellitus. These associations are not unexpected
given the clustering of such risk factors in individuals with
the metabolic syndrome. Studies have shown that among the
nearly 4000 individuals with diabetes mellitus reported in the
Pan-European survey, the prevalence of low HDL-C was
50% higher in those with compared with those without
diabetes mellitus.29 Similarly, the greater propensity for low
HDL-C in some specific populations (eg, Indians versus other
ethnic groups) may be explained in part by their increased
susceptibility to central fat accumulation.30
Although low HDL-C is associated with several rare
genetic diseases, including hypoalphalipoproteinemia, the
cause for isolated low HDL-C at the population level remains
largely unknown, although factors such as low levels of
physical activity, obesity, and avoidance of alcohol are
known to be associated with low HDL-C levels. It is therefore
possible that variations in diet, alcohol consumption, and
physical activity will explain some of the variability between
populations. For example, several studies have demonstrated
heterogeneity in plasma lipid responses to different levels of
dietary fat consumption that may indicate an epigenetic
effect.31,32
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Figure 3. Adjusted hazard ratios (HRs)
and 95% confidence intervals (CIs) for
stroke associated with high-density lipo-
protein cholesterol (HDL-C) levels by
region, sex, and smoking status (current
vs not) from studies included in the Asia
Pacific Cohort Studies Collaboration. ANZ
indicates Australia/New Zealand; Normal
HDL-C, normal levels of HDL-C; isolated,
isolated low levels of HDL-C; and low, low
levels of HDL-C and high LDL-C and/or
high triglycerides. The 3 groups are mutu-
ally exclusive. P for regional, sex, and
smoking interaction�0.51, 0.51, and 0.88,
respectively.
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This study has several limitations. First, the ethnic group-
ings we use are crude and do not take into account the
potential variation in genetic differences between Asian
populations; we did not have sufficient data to reliably
characterize the phenotypes of individuals with isolated low
HDL-C by country. Second, given the westernization of
many countries across Asia in recent years and the corre-
sponding increase in the prevalence of factors that negatively
affect HDL-C levels, such as obesity and low levels of
physical activity, the mean population level of HDL-C may
have shifted recently to a greater extent in the Asian cohorts.
Third, a significant proportion of the included studies are
cross-sectional, which precludes examination of the temporal
nature of the association between lipids and risk factors.
Fourth, there will have been both interstudy and intrastudy
measurement errors in the ascertainment of lipid measure-
ments. However, the measurement error is likely to have been
random and present across all studies. There may also have
been some bias introduced by the different methods used to
verify cardiovascular outcomes across the APCSC studies.
Finally, data on apolipoproteins and lipid-lowering therapy
were not routinely recorded in the majority of studies in-
cluded in both the OAC and APCSC, which may have
facilitated a more intricate analysis of the data. For example,
information on the use of cholesterol-lowering drugs was
available in �5% of the entire study population. Statin use is
likely to have been uncommon, given that the baseline year of
recruitment for these studies ranged from 1966 to 1994. It is
possible, however, that LDL-C–lowering therapy, eg, with
fibrates or nicotinic acid, which also increases HDL-C,33
would have been more common in Australia and New
Zealand compared with other countries in the Asia-Pacific
region. However, data from the pan-European Survey suggest
that levels of HDL-C are broadly similar in individuals with
and without lipid-lowering therapy.34
Conclusions
Isolated low level of HDL-C is a phenotype that appears to be
particularly common in Asian populations. Individuals exhib-
iting this form of lipid abnormality are at increased risk of
CHD, but, at the same time, are unlikely to be candidates for
lipid-lowering medication because their levels of triglycer-
ides and LDL-C meet targets proposed by current guidelines.
These regions will potentially benefit from strategies that can
increase levels of HDL-C, such as effective smoking cessa-
tion campaigns and initiatives that result in sustained weight
loss and increases in physical activity at the population level.
Moreover, agents such as niacin and fibrates may be partic-
ularly important in Asia. Furthermore, going forward, new
drugs such as cholesteryl ester transfer protein inhibitors may
be important in cardiovascular prevention in the region.
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CLINICAL PERSPECTIVE
This study, comprising information from �220 000 individuals from the Asia-Pacific region, describes a novel and
potentially important form of dyslipidemia. Low levels of high-density lipoprotein cholesterol (HDL-C) have been
independently associated with increased cardiovascular risk. Some earlier observational studies have suggested the
existence of such a distinct type of dyslipidemia with low HDL-C occurring in the absence of elevated levels of other lipid
fractions, ie, isolated low HDL-C. This phenotype has been postulated to be especially prevalent among Asian populations.
Individuals with this form of lipid abnormality are usually not considered to be candidates for lipid-lowering medication
because of their comparatively normal levels of total and low-density lipoprotein cholesterol. This study compared the
prevalence of isolated low HDL-C in Asian and non-Asian populations and determined whether the risk of coronary heart
disease and stroke was elevated in individuals with this form of lipid abnormality. Findings from this study indicated a
substantially higher prevalence of isolated low HDL-C among Asians (22.4%) compared with non-Asians (14.5%) that was
unlikely to be explained by differences in the background rates of lipid-lowering medication, cigarette smoking, and
alcohol use. Both nonisolated low HDL-C and isolated low HDL-C were associated with increased risk of coronary heart
disease but not stroke. Compared with non-Asians, the relationship between isolated low HDL-C and subsequent risk of
coronary heart disease was stronger in Asians. In this group, it was associated with the same magnitude of coronary risk
(�60%) as low levels of HDL-C combined with other lipid abnormalities.
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